Clay B. Siegell, is an ambitious man who has effortlessly and tirelessly worked to see his dreams come to pass. Mr. Siegell is a scientist by training, and he has majored mainly in cancer therapists. He graduated with Bachelor of Science (BS) from the University of Maryland where he specialized in Zoology, and he is also a Ph.D. holder of Genetics from George Washington University.
After his first graduation, Dr. Siegell has held several positions where he has been impacting the lives of people through his experience and the greet passion he has for humankind. In 2006 he was appointed as Director on the Board of Directors of Alder Biopharmaceuticals Inc., Mirna Therapheuticals Inc. in 2013, in the year 2014, he was also appointed as the Director on the Board of Directors of UltraGenyx Pharmaceuticals, positions he has secured to date. The position has helped him guide the companies in the development of Anti-Drug Conjugates (ADC).
Due his passion and experience in science and technology, Dr. Siegell co-founded the biotechnology Seattle Genetics. The firm is established of scientific invention, research and drug improvement practices as well as the desire for helping cancer patients. The company is one of the leading organizations in the medical industry that deals with Anti-Drugs Conjugates or ADC. This technology mainly intended to connect the targeting ability to distribute cell killing agents to cancer cells.
Seattle Genetics Company was founded in 1998, and its head offices are located in Bothell Washington Dc, a suburb of Seattle. It completed its public offering in March 2001. Over the years it has recorded tremendous growth and has been operating in more than 50 countries including the US, Canada, Japan, and members of the European Union. It has more than 800 employees, all with passion and responsibility of helping people living with cancer.
Seattle Genetics ADC technology has been a success that has been achieved through collaborating with other organizations that are using Seattle Genetics multiple programs approach to empower antibodies. Through their extensive researches, developments, collaborations, and scientific innovations they are dedicated to advance patient’s treatment. Since its initial public offering, Seattle Genetics has been trading on the Nasdaq Stock Market under the initials SGEN.